(CTSO) Cytosorbents Crp - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US23283X2062
CTSO: Blood Purification Devices, Cytokine Adsorbers, Medical Devices
Cytosorbents Corporation (NASDAQ:CTSO) is a medical device company specializing in blood purification technologies. Its core platform leverages a proprietary adsorbent and porous polymer technology to develop devices for critical care and other applications. The company operates in the U.S., Germany, and internationally. Its lead product, CytoSorb, is an extracorporeal cytokine adsorber used in sepsis treatment, perioperative complication management, and organ transplant quality enhancement. The product portfolio also includes VetResQ, a veterinary device for sepsis and pancreatitis treatment in animals. The company is expanding its pipeline with CytoSorb-XL for sepsis and critical illnesses, HemoDefend for blood purification, K+ontrol for hyperkalemia treatment, and ContrastSorb for contrast removal during imaging procedures. Additional developmental products include BetaSorb for renal failure, DrugSorb for drug removal, and DrugSorb-ATR, an antithrombotic removal system. Originally named MedaSorb Technologies Corporation, the company rebranded as Cytosorbents Corporation in 2010. Founded in 1997, it is headquartered in Princeton, New Jersey.
Additional Sources for CTSO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CTSO Stock Overview
| Market Cap in USD | 63m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 2013-11-07 |
CTSO Stock Ratings
| Growth 5y | -60.9% |
| Fundamental | -15.4% |
| Dividend | 0.0% |
| Rel. Strength Industry | 6.19 |
| Analysts | 4/5 |
| Fair Price Momentum | 0.89 USD |
| Fair Price DCF | - |
CTSO Dividends
No Dividends PaidCTSO Growth Ratios
| Growth Correlation 3m | 70.5% |
| Growth Correlation 12m | 43.3% |
| Growth Correlation 5y | -90.8% |
| CAGR 5y | -25.12% |
| CAGR/Max DD 5y | -0.27 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -1.47 |
| Beta | 0.80 |
| Volatility | 96.72% |
| Current Volume | 85.2k |
| Average Volume 20d | 89.1k |
As of March 14, 2025, the stock is trading at USD 1.07 with a total of 85,196 shares traded.
Over the past week, the price has changed by +1.90%, over one month by -18.32%, over three months by +5.94% and over the past year by +5.94%.
Neither. Based on ValueRay Fundamental Analyses, Cytosorbents Crp is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -15.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CTSO as of March 2025 is 0.89. This means that CTSO is currently overvalued and has a potential downside of -16.82%.
Cytosorbents Crp has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy CTSO.
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CTSO Cytosorbents Crp will be worth about 1 in March 2026. The stock is currently trading at 1.07. This means that the stock has a potential downside of -9.35%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 5 | 367.3% |
| Analysts Target Price | 5 | 367.3% |
| ValueRay Target Price | 1 | -9.3% |